论文部分内容阅读
目的:观察重组人白细胞介素11(rhIL11)治疗实体瘤和急性白血病(AL)患者化疗后血小板减少的疗效及安全性。方法:实体瘤患者25例、AL患者20例,于化疗结束后BPC≤30×109/L时予rhIL1150μg/(kg·d)皮下注射,连用7～14天或BPC升高至≥60×109/L时停药,用药期间隔天查血常规1次,观察外周血BPC变化、皮肤出血情况及rhIL11应用的不良反应。以同期未用rhIL11治疗的15例实体瘤和10例AL患者作对照。结果:治疗组用药后1周和2周,BPC在实体瘤患者分别为(67.68±9.3)×109/L、(86.55±12.76)×109/L;在AL患者分别为(69.83±7.68)×109/L、(87.17±8.66)×109/L。治疗组较对照组BPC恢复时间缩短(P<0.05)。常见不良反应为轻度乏力、肌肉疼痛。3例出现短暂房性心律失常,减量或停药后消失。结论:rhIL11治疗实体瘤和AL患者化疗后引起的血小板减少安全有效,可使BPC恢复加快,并有效缓解出血症状。
Objective: To observe the efficacy and safety of recombinant human interleukin 11 (rhIL11) in the treatment of thrombocytopenia after chemotherapy in patients with solid tumors and acute leukemia (AL). Methods: Twenty-five patients with solid tumor and 20 patients with AL were treated with rhIL1150μg/(kg·d) subcutaneously after BPC≤30×109/L after chemotherapy, and continued for 7～14 days or BPC increased to ≥60×109. When the drug was stopped at the time of /L, the routine blood test was conducted once a day to observe changes in peripheral blood BPC, skin bleeding, and adverse reactions of rhIL11 application. In the same period, 15 solid tumors that were not treated with rhIL11 and 10 AL patients were used as controls. Results: One week and two weeks after treatment in the treatment group, BPC in solid tumors were (67.68±9.3)×109/L, (86.55±12.76)×109/L, respectively; in AL patients were (69.83±7.68)× 109/L, (87.17±8.66)×109/L. The recovery time of BPC in the treatment group was shorter than that in the control group (P<0.05). Common adverse reactions are mild fatigue, muscle pain. Three patients had transient atrial arrhythmias and disappeared after reduction or withdrawal. Conclusion: The thrombocytopenia induced by chemotherapy with rhIL11 in solid tumors and AL patients is safe and effective. It can accelerate the recovery of BPC and effectively relieve bleeding.